Clinical Research Directory
Browse clinical research sites, groups, and studies.
Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection
Sponsor: Vancouver Coastal Health
Summary
This study aims to use mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy\_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with Mycobacterium abscessus with goal to reduce infection burden and improve pulmonary disease
Official title: Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection: An Open Label Individual Patient Study
Key Details
Gender
FEMALE
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
1
Start Date
2025-11
Completion Date
2027-10
Last Updated
2025-11-17
Healthy Volunteers
No
Interventions
Mycobacteriophage Muddy_HRMN0052
In-vitro effective Mycobacteriophage Muddy\_HRMN0052 against specific strain of Mycobacterium abscessus ssp abscessuss
Amikacin Injection
Amikacin 1000mg IV 3x/wk
Clofazimine
Clofazimine 100mg PO OD
Bedaquiline (B)
Bedaquiline 400mg PO OD x 2 weeks then 200mg PO 3x/wk (Alternate agent if toxicity/intolerance to amikacin or clofazimine to ensure on 2 antibiotics throughout)
Linezolid (LZD)
Linezolid 600mg PO OD (dose reduce to 600mg PO 3x/wk if adverse effects)(Alternate agent if toxicity/intolerance to amikacin or clofazimine to ensure on 2 antibiotics throughout)
Sulfamethoxazole/Trimethoprim
Sulfamethoxazole/Trimethoprim 800/160mg PO BID (Alternate agent if toxicity/intolerance to amikacin or clofazimine to ensure on 2 antibiotics throughout)
Locations (1)
Vancouver General Hospital Non-Tuberculous Mycobacterial Disease Clinic
Vancouver, British Columbia, Canada